Summary
Welcome to the fourth edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news, including the global regulatory landscape, biosimilars articles and reports, and company news as reported via company press releases. The “hot topic” for this edition discusses the crucial, but often overlooked, part played of bioanalytical method development and validation in the marketing authorization of a Biosimilar and safety of patients. The article discusses several of the practical steps which should be taken into account during validation and bioanalysis required to determine pharmacokinetics (PK), to monitor immunogenicity (anti-drug antibody, ADA, assays), and to assess key pharmacodynamic parameters (PD).
Register to download
Biosimilars Newsletter Volume 4, October 2014
You may also be interested in:
Webcast
Biobetters: Challenges and Opportunities
Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars,…
Fact Sheet
LC-MS/MS Support for Studies with Large Molecules
PRA’s Bioanalytical Laboratories provide LC-MS/MS services to support clients’ studies with biological and small molecules. The information details…
White Paper
The Value Of Biobetters
The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biologics are expected to account for approximately 17% of total…